Implementation of pharmacokinetic-guided dosing of prophylaxis in hemophilia patients

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Albutrepenonacog alfa (Primary) ; Efmoroctocog alfa (Primary) ; Eftrenonacog alfa (Primary) ; Factor IX (Primary) ; Factor VIII/von Willebrand factor (Primary) ; Lonoctocog alfa (Primary) ; Moroctocog alfa (Primary) ; Nonacog alfa (Primary) ; Nonacog alfa (Primary) ; Nonacog beta pegol (Primary) ; Nonacog gamma (Primary) ; Octocog alfa (Primary) ; Octocog alfa (Primary) ; Octocog alfa (Primary) ; Rurioctocog alfa pegol (Primary) ; Simoctocog alfa (Primary) ; Turoctocog alfa (Primary)
Indications Haemophilia A; Haemophilia B
Focus Pharmacokinetics
Acronyms OPTI-CLOT: TARGET

01 Jun 2020 Results (n=59) evaluating von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients, published in the Thrombosis and Haemostasis
16 May 2019 Status changed from not stated to recruiting.
27 Dec 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com